Report cover image

Neurodegenerative Disease Market Forecasts to 2032 – Global Analysis By Molecule Type (Small-Molecule Drugs, Biologics and Cell & Gene Therapies), Indication, Drug Class, Route of Administration, End User and By Geography

Publisher Stratistics Market Research Consulting
Published Oct 30, 2025
Length 200 Pages
SKU # SMR20511110

Description

According to Stratistics MRC, the Global Neurodegenerative Disease Market is accounted for $64.4 billion in 2025 and is expected to reach $118.9 billion by 2032 growing at a CAGR of 9.15% during the forecast period. Neurodegenerative disease refers to a group of disorders characterized by the progressive loss of structure or function of neurons, leading to their gradual death. These conditions affect the brain and nervous system, impairing cognitive, motor, and sensory functions. Common examples include Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS). The underlying causes often involve abnormal protein accumulation, genetic mutations, oxidative stress, and mitochondrial dysfunction. As neurons cannot regenerate efficiently, these diseases are typically chronic and worsen over time. Neurodegenerative diseases pose significant medical and social challenges due to their complexity and lack of curative treatments.

Market Dynamics:

Driver:

Advances in biomarker & diagnostic technology

Researchers are developing fluid-based and imaging biomarkers to identify early-stage pathology in Alzheimer’s, Parkinson’s, and ALS. Integration with AI and machine learning is improving diagnostic accuracy and disease stratification. Pharmaceutical companies are using biomarkers to optimize trial design and therapeutic targeting. Companion diagnostics are gaining traction across precision neurology pipelines. These capabilities are propelling innovation in early intervention and personalized care.

Restraint:

Complex disease biology & heterogeneity

Many conditions involve multifactorial pathogenesis, including genetic, environmental, and inflammatory components. Disease progression varies widely across individuals, complicating trial endpoints and treatment response. Lack of validated animal models and translational biomarkers slows preclinical research. Regulatory bodies require robust evidence for efficacy and safety in heterogeneous populations. These challenges continue to hinder drug development and platform scalability.

Opportunity:

Rising healthcare spending & awareness

Governments are funding national dementia strategies and aging-related research programs. Public campaigns are improving awareness and reducing stigma around cognitive decline and neurological disorders. Hospitals are expanding memory clinics and neurorehabilitation centers to meet rising demand. Investment in digital health and remote monitoring is supporting long-term care and disease management. These trends are fostering growth across prevention, diagnosis, and therapeutic innovation.

Threat:

Limited diagnostic access in low-resource settings

Many regions lack trained neurologists, imaging infrastructure, and molecular testing capabilities. Rural and underserved populations face delays in diagnosis and limited access to specialized care. Cost and availability of PET scans, CSF assays, and genetic testing remain barriers in emerging markets. Fragmented referral pathways and low public awareness further degrade care quality. These constraints continue to hamper equity and outcomes across global neurodegenerative ecosystems.

Covid-19 Impact:

The pandemic disrupted clinical trials, diagnostics, and long-term care for neurodegenerative patients worldwide. Lockdowns and resource reallocation delayed therapy access and disease monitoring. However, post-pandemic recovery strategies have emphasized resilience and digital transformation in neurology care. Telemedicine, remote cognitive assessments, and digital biomarkers gained traction across aging populations. Public awareness of neurological health increased during the crisis, influencing policy and research priorities. These shifts are accelerating investment in infrastructure, innovation, and patient-centric care models.

The alzheimer’s disease segment is expected to be the largest during the forecast period

The alzheimer’s disease segment is expected to account for the largest market share during the forecast period due to its high prevalence, diagnostic complexity, and therapeutic innovation. Pharmaceutical firms are launching monoclonal antibodies and disease-modifying therapies targeting amyloid and tau pathology. Investment in early detection and risk stratification is rising across aging populations. Integration with digital cognitive tools and fluid biomarkers is improving screening and monitoring. Governments are funding dementia research and care coordination programs.

The cell & gene therapies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cell & gene therapies segment is predicted to witness the highest growth rate as curative approaches gain traction across rare and progressive neurodegenerative conditions. Developers are using viral vectors, stem cells, and gene editing platforms to restore neuronal function and halt disease progression. Regulatory bodies are offering expedited review and conditional approvals for breakthrough therapies. Investment in manufacturing scale-up and delivery platforms is improving readiness and affordability. Partnerships between biotech firms, hospitals, and payers are supporting access and reimbursement models.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure, regulatory engagement, and aging demographics. The United States and Canada host major neurology centers, clinical trial networks, and patient advocacy organizations. FDA programs such as Fast Track and Breakthrough Therapy Designation are supporting innovation and market entry. Investment in biomarker development and precision neurology is driving platform expansion. Presence of leading biotech firms and academic institutions is reinforcing leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, aging populations, and policy reform converge. Countries like China, Japan, India, and South Korea are scaling neurology diagnostics and therapy access across urban and rural regions. Government-backed programs are supporting dementia screening, public awareness, and infrastructure development. Regional biotech firms are launching cell and gene therapies tailored to population-specific indications. Demand for affordable and scalable solutions is rising across public and private healthcare systems. These trends are accelerating regional growth across neurodegenerative disease ecosystems.

Key players in the market

Some of the key players in Neurodegenerative Disease Market include AbbVie Inc., Amneal Pharmaceuticals LLC, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., Biogen Inc., Eli Lilly and Company, Johnson & Johnson, Eisai Co., Ltd., Lundbeck A/S and Denali Therapeutics Inc.

Key Developments:

In January 2025, AbbVie exercised its first opt-in under the collaboration with Capsida Biotherapeutics, securing rights to a gene therapy program for neurodegenerative diseases. The decision followed promising primate data showing effective delivery of AbbVie’s therapeutic payload to the brain using Capsida’s engineered AAV capsids, while minimizing off-target effects in the liver and dorsal root ganglia.

In September 2023, Amneal launched IPX203 in the U.S. following FDA approval for Parkinson’s disease. The extended-release formulation demonstrated superior “on-time” versus immediate-release carbidopa-levodopa in Phase 3 trials, offering improved symptom control and dosing convenience for patients with advanced Parkinson’s.

Molecule Types Covered:
• Small-Molecule Drugs
• Biologics
• Cell & Gene Therapies

Indications Covered:
• Alzheimer’s Disease
• Parkinson’s Disease
• Huntington’s Disease
• Amyotrophic Lateral Sclerosis (ALS)
• Multiple Sclerosis (MS)
• Spinal Muscular Atrophy (SMA)
• Other Indications

Drug Classes Covered:
• N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Dopamine Agonists & Inhibitors
• Cholinesterase Inhibitors
• Monoclonal Antibodies
• Gene & RNA-Based Therapies
• Other Drug Classes

Route of Administrations Covered:
• Oral
• Injectable
• Transdermal
• Intranasal

End Users Covered:
• Hospitals & Clinics
• Research & Academic Institutes
• Pharmaceutical & Biotech Companies
• Patient Advocacy Groups
• Other End-Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Table of Contents

200 Pages
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Neurodegenerative Disease Market, By Molecule Type
5.1 Introduction
5.2 Small-Molecule Drugs
5.3 Biologics
5.4 Cell & Gene Therapies
6 Global Neurodegenerative Disease Market, By Indication
6.1 Introduction
6.2 Alzheimer’s Disease
6.3 Parkinson’s Disease
6.4 Huntington’s Disease
6.5 Amyotrophic Lateral Sclerosis (ALS)
6.6 Multiple Sclerosis (MS)
6.7 Spinal Muscular Atrophy (SMA)
6.8 Other Indications
7 Global Neurodegenerative Disease Market, By Drug Class
7.1 Introduction
7.2 N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
7.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
7.4 Dopamine Agonists & Inhibitors
7.5 Cholinesterase Inhibitors
7.6 Monoclonal Antibodies
7.7 Gene & RNA-Based Therapies
7.8 Other Drug Classes
8 Global Neurodegenerative Disease Market, By Route of Administration
8.1 Introduction
8.2 Oral
8.3 Injectable
8.4 Transdermal
8.5 Intranasal
9 Global Neurodegenerative Disease Market, By End User
9.1 Introduction
9.2 Hospitals & Clinics
9.3 Research & Academic Institutes
9.4 Pharmaceutical & Biotech Companies
9.5 Patient Advocacy Groups
9.6 Other End-Users
10 Global Neurodegenerative Disease Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 AbbVie Inc.
12.2 Amneal Pharmaceuticals LLC
12.3 Boehringer Ingelheim GmbH
12.4 F. Hoffmann-La Roche Ltd.
12.5 Merck & Co., Inc.
12.6 Novartis AG
12.7 Pfizer Inc.
12.8 Teva Pharmaceutical Industries Ltd.
12.9 UCB S.A.
12.10 Biogen Inc.
12.11 Eli Lilly and Company
12.12 Johnson & Johnson
12.13 Eisai Co., Ltd.
12.14 Lundbeck A/S
12.15 Denali Therapeutics Inc.
List of Tables
Table 1 Global Neurodegenerative Disease Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Neurodegenerative Disease Market Outlook, By Molecule Type (2024-2032) ($MN)
Table 3 Global Neurodegenerative Disease Market Outlook, By Small-Molecule Drugs (2024-2032) ($MN)
Table 4 Global Neurodegenerative Disease Market Outlook, By Biologics (2024-2032) ($MN)
Table 5 Global Neurodegenerative Disease Market Outlook, By Cell & Gene Therapies (2024-2032) ($MN)
Table 6 Global Neurodegenerative Disease Market Outlook, By Indication (2024-2032) ($MN)
Table 7 Global Neurodegenerative Disease Market Outlook, By Alzheimer’s Disease (2024-2032) ($MN)
Table 8 Global Neurodegenerative Disease Market Outlook, By Parkinson’s Disease (2024-2032) ($MN)
Table 9 Global Neurodegenerative Disease Market Outlook, By Huntington’s Disease (2024-2032) ($MN)
Table 10 Global Neurodegenerative Disease Market Outlook, By Amyotrophic Lateral Sclerosis (ALS) (2024-2032) ($MN)
Table 11 Global Neurodegenerative Disease Market Outlook, By Multiple Sclerosis (MS) (2024-2032) ($MN)
Table 12 Global Neurodegenerative Disease Market Outlook, By Spinal Muscular Atrophy (SMA) (2024-2032) ($MN)
Table 13 Global Neurodegenerative Disease Market Outlook, By Other Indications (2024-2032) ($MN)
Table 14 Global Neurodegenerative Disease Market Outlook, By Drug Class (2024-2032) ($MN)
Table 15 Global Neurodegenerative Disease Market Outlook, By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (2024-2032) ($MN)
Table 16 Global Neurodegenerative Disease Market Outlook, By Selective Serotonin Reuptake Inhibitors (SSRIs) (2024-2032) ($MN)
Table 17 Global Neurodegenerative Disease Market Outlook, By Dopamine Agonists & Inhibitors (2024-2032) ($MN)
Table 18 Global Neurodegenerative Disease Market Outlook, By Cholinesterase Inhibitors (2024-2032) ($MN)
Table 19 Global Neurodegenerative Disease Market Outlook, By Monoclonal Antibodies (2024-2032) ($MN)
Table 20 Global Neurodegenerative Disease Market Outlook, By Gene & RNA-Based Therapies (2024-2032) ($MN)
Table 21 Global Neurodegenerative Disease Market Outlook, By Other Drug Classes (2024-2032) ($MN)
Table 22 Global Neurodegenerative Disease Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 23 Global Neurodegenerative Disease Market Outlook, By Oral (2024-2032) ($MN)
Table 24 Global Neurodegenerative Disease Market Outlook, By Injectable (2024-2032) ($MN)
Table 25 Global Neurodegenerative Disease Market Outlook, By Transdermal (2024-2032) ($MN)
Table 26 Global Neurodegenerative Disease Market Outlook, By Intranasal (2024-2032) ($MN)
Table 27 Global Neurodegenerative Disease Market Outlook, By End User (2024-2032) ($MN)
Table 28 Global Neurodegenerative Disease Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
Table 29 Global Neurodegenerative Disease Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
Table 30 Global Neurodegenerative Disease Market Outlook, By Pharmaceutical & Biotech Companies (2024-2032) ($MN)
Table 31 Global Neurodegenerative Disease Market Outlook, By Patient Advocacy Groups (2024-2032) ($MN)
Table 32 Global Neurodegenerative Disease Market Outlook, By Other End-Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us